å»è¬åå ¬è¡šãããæŽå¯
æ¥æ§ãªã³ãèœçæ§çœè¡ç(ALL)ã¯ã骚é«ãè¡æ¶²ã«åœ±é¿ãäžããçã®äžçš®ã§ãã æ¡ä»¶ã¯ããªã³ãèœçްèãšãåŒã°ããèªç¶çœè¡çã®éå°çç£ã«ãã£ãŠç¹åŸŽä»ããããŸãã äžåäžãŸãã¯ç°åžžãªçްèã¯ãé©åã«æ©èœããå¥åº·ãªçްèã®åšãã«æ§ç¯ããããšã¯ã§ããŸããã ãã¹ãŠã®æ£è ã¯ãåçºææãè²§è¡ãåºè¡ãããã³éªšé«ãèµ€è¡çãçœè¡çããã³è¡å°æ¿ã®ååãªæ°ã圢æã§ããªãããã容æã«å·ã€ãããšã¯éåžžã«ææã§ãã ããã¯é«ãé²è¡çãç¹åŸŽãšããæ°ãæä»¥å ã«æ²»çããªããšèŽåœçã§ããã ãã现èã¯ããªã³ãç¯ãèèãèŸèãäžæ¢ç¥çµç³»ãå«ãäœã®ä»ã®èåšã«åºããå¯èœæ§ãããã ç¶æ ã®äžè¬çãªçç¶ã«ã¯ãè äžå šãèºçãåŒåžåšçŸæ£ãããã³éªšã®ç... ãã£ãšèŠã
äºæ¬¡ç²ç¶è ºæ©èœäº¢é²ç(SHPT)ã¯ãäž»ã«ç²ç¶è ºãã«ã¢ã³ãããã©ã«ä»£è¬ç°åžžãããã³å¯ç²ç¶è ºæ©èœäº¢é²çã®é«ã¬ãã«ã«ãã£ãŠç¹åŸŽä»ããããæ ¢æ§è çŸæ£(CKD)ãšé¢é£ããæ·±å»ãªãå ±éããã³é²è¡å䜵çã®1ã€ãæããŸãã ç æ°ã®è èã¯ããã¿ãã³Aããã®æŽ»æ§åœ¢æ ã«å€ããããšãã§ããªããããäœå ã§äžæº¶æ§ã«ã«ã·ãŠã ãªã³é žå¡©ã®åœ¢æã«é©ããªããããäºæ¬¡ç²ç¶è ºæ©èœäº¢é²ã«ã€ãªããã ç æ°ã®äžè¬çãªåŸŽåããã³åŸŽåã¯éªšããã³æ¥åç®æã®èŠçããŸãè¢ã®å€åœ¢ãå«ãã§ããŸãã äºæ¬¡ç²ç¶è ºæ©èœäº¢é²çã®æ£è ã«åŒãèµ·ããããé害ã¯ãçåœãšçåœã®æåŸ ã®æªãå質ã«ã€ãªããå¯èœæ§ããããŸãã SHPTã®ããã®åŠçœ®ã¯å諟ãããã¿ãŒã²ããåºåå ã®å¯... ãã£ãšèŠã
å»è¬åã°ã¬ãŒãã®æ°Žé žåãã°ãã·ãŠã åžå ŽãçŽåºŠå¥ (99%)ããšã³ããŠãŒã¶ãŒå¥ (補è¬äŒç€Ÿãåèšç ç©¶æ©é¢ããã®ä»)ãå°åå¥ (åç±³ããšãŒããããã¢ãžã¢å€ªå¹³æŽãã©ãã³ã¢ã¡ãªã«ãäžæ±ãã¢ããªã«)... ãã£ãšèŠã
ãã£ãŒã«ãã®é²æ© ãã€ãªãã¯ãããžãŒ è¬ã®åµè¬ããã»ã¹ãéããŠãè¬ã®åœ¢ã§æå¹æåãèå¥ããããã«ãå»è¬åã¯åŸã ã«åžå Žã§ããŒã¹ãäžããŠããŸãã ãã®è¬ã®çºèŠããã»ã¹ã¯ãååŠçã©ã€ãã©ãªã®ã¹ã¯ãªãŒãã³ã°ãèªç¶çæ³ã®ããã®æå¹æåã®ç¹å®ããŸãã¯éèã®çºèŠãå«ã¿ãŸãã ãŠã€ã«ã¹ãŸãã¯æææ§çŸæ£ãå«ãæ°ããç æ°ã®å䜵çã¯ããããã®æ¡ä»¶ã®è¬ç©çºèŠã®éèŠãé«ãã ããããè¬ã®éçºã¯è€éã§ãã³ã¹ãããããããªã¹ã¯ã®ããããã»ã¹ã§ããè¬ã®çºèŠã®ç®çã¯æ®µéãåèšåºç ç©¶ã«ãã£ãŠèª¿æ»ã®è¬å€ã®æåçã調æ»ã®æ°ããè¬å€ã®å¡åžç·éIãèªèããããšã§ãã 第IIçžã第IIIçžè©Šéšãæ°è¬å¿çšã第IVçžè©Šéšã åµè¬ããã»ã¹ã®æå... ãã£ãšèŠã
ã€ã³ãã®ãã¥ãŒãã©ã·ã¥ãŒãã£ã«ã«ãºã³ã©ãŒã²ã³åžå Žã補åã¿ã€ãå¥ïŒãŒã©ãã³ãå æ°Žåè§£ã³ã©ãŒã²ã³ã倩ç¶ã³ã©ãŒã²ã³ãåæã³ã©ãŒã²ã³ïŒãäŸçµŠæºå¥ïŒåç©ããŒã¹ããã³æ€ç©ããŒã¹ïŒã補å€å¥ïŒç²æ«ãã¯ãªãŒã ããã§ã€ã¹ãã¹ã¯/ãã§ã€ã¹ã·ãŒããã°ããã«ãã»ã«ã溶液ãªã©ïŒãçšéå¥ïŒãã¢ã±ã¢ããªãŒã©ã«ã±ã¢ãã¹ãã³ã±ã¢ãã¢ã€ã±ã¢ãæŽåœ¢å€ç§ã±ã¢ãããã³ ãã®ä»ïŒã販売ãã£ãã«å¥ïŒãªã³ã©ã€ã³ããã³ãªãã©ã€ã³ïŒ... ãã£ãšèŠã
æ ¢æ§èºã¢ã¹ãã«ã®ã«ç(CPA)ã¯ãäžççãªèå»¶ã䌎ãèºã®æ·±å»ãªé·æçèçŸæ£ã§ãã æ ¢æ§èºã¢ã¹ãã«ã®ã«ç(CPA)ã¯ãçµæ žãæ ¢æ§é塿§èºçŸæ£ããã³ãµã«ã³ã€ããŒã·ã¹ãå«ãæ¡ä»¶ãè€éã«ããé«ã眹æ£çãšæ»äº¡çã«é¢é£ããŠããŸãã æ ¢æ§ã®èºã¢ã¹ãã«ã®ã«ç(CPA)ã¯ãèºãã«ããã®ãã£ãããšé²è¡çç Žå£ã«ãã£ãŠç¹åŸŽä»ããããŸããè€æ°ã®ãã£ããã£ãããŒãã«ãã€ã³ãã£ã«ããŸãã¯ç·ç¶çã®åäžã®åœ¢æ ã§ã¯ãã¢ã¹ãã«ã®ã«ãã®æç¡ã«ããããããäžççãªæ ¢æ§ã¢ã¹ãã«ã®ã«çæ²»çåžå Žã¯ãè©äŸ¡ããããšæšå®ããã US$ 2,916.3 çŸäžå ãåãåãã 2021幎 å±ç€ºäºå® ã«ã°ã¬ ã«ã€ã㊠4.8ããŒã»ã³ã äºå ±æéäž (2... ãã£ãšèŠã
Eisenmengerã·ã³ãããŒã ã¯é«ãããéçºããŸã è¡å§ èºã§ã¯ãèºé«è¡å§ãšããŠç¥ãããŠããã èºé«è¡å§ã¯ãç¹å®ã®å 倩æ§å¿ãå¿èã®å·ŠåŽããå³åŽã«ç°åžžã«æµããããã«è¡æ¶²ãåŒãèµ·ããåå ã§èµ·ãããŸã(å·Šããå³ãž)ã ãã®æ¡ä»¶ãåŒãèµ·ãããå 倩ã®å¿æ¬ é¥ã¯ãç¹èš±å€§è žåè硬åç(PDA)ãã¢ããªã«ã®é颿§æ¬ æ(ASD)ããã³ããªã«ã®éèæ¬ é¥(VSD)ãããã³ã¢ãªãªãã³ãã©ã«éæ²³ã®æ¬ é¥(AVéæ²³)ãå«ã¿ãŸãã ãã®shuntã®é転ã¯ãå¿èã®å³åŽããå·ŠåŽ(å³ããå·Šã®ã·ã£ã³ã)ãžã®è¡ã®éåã¯ãè¡æ¶²äžã®äžååãªé žçŽ äŸçµŠãåŒãèµ·ãããŸãã ãã®é転ã¯ãå¿èã®å³åŽã«è¡å§ãå¢å ãããããšã«ããèµ·ãããè¡æ¶²ãå·ŠåŽã«... ãã£ãšèŠã
ç±³åœã¡ãŒã«ãŒåŠæ¹è¬ã¯ãŒãã³åžå Žãå²åŒã¿ã€ãå¥ïŒã¡ãŒã«ãŒè²¯èã«ãŒããåŠæ¹ç®å²åŒã«ãŒããè¬å±å²åŒã¯ãŒãã³ïŒãæ²»çåéå¥ïŒç³å°¿ç ãæãŠã€ã«ã¹è¬ãæé¢ç¯çè¬ãæé«èè¡çè¬ãåŒåžåšè¬ãçŒç§è¬ãè «çåŠãé®çè¬ãæææçè¬ããã®ä»ïŒãæµéãã£ãã«å¥ïŒãªã³ã©ã€ã³ããã³ãªãã©ã€ã³ïŒ... ãã£ãšèŠã
æ°Žç£é€æ®ã¯ã¯ãã³åžå Žãçš®å¥ïŒéãç²æ®»é¡ãè»äœåç©ãªã©ïŒãã¯ã¯ãã³ã®çš®é¡å¥ïŒäžæŽ»åïŒæ»æ» ïŒã¯ã¯ãã³ãç匱æ¯åã¯ã¯ãã³ãDNAã¯ã¯ãã³ãªã©ïŒãç åäœã®çš®é¡å¥ïŒçްèã¯ã¯ãã³ããŠã€ã«ã¹ã¯ã¯ãã³ãå¯çè«ã¯ã¯ãã³ãªã©ïŒããšã³ããŠãŒã¶ãŒå¥ïŒåæ¥æ°Žç£é€æ®å Žãåµåå Žãç ç©¶æ©é¢ããã³å€§åŠãªã©ïŒãå°çå¥ (åç±³ããšãŒããããã¢ãžã¢å€ªå¹³æŽãã©ãã³ã¢ã¡ãªã«ãäžæ±ãã¢ããªã«)... ãã£ãšèŠã
èèç·ç¶çã¯ç¹å®ã®ç¶æ ã§ã¯ãªããå¥ã®èèã®åé¡ã®çç¶ã§ã¯ãããŸããã èç·ç¶çã¯çç¶èªäœãåŒãèµ·ãããŸããã ãã«ã¹ã±ã¢ã®å°éå®¶ã¯ãèç·ç¶çã®åå ãæ²»çããããšã«ãããèç·ç¶çã®æ²»çã«çŠç¹ãåãããèèã®ç¢çã黿¢ãŸãã¯é ãããŸãã æ ¢æ§ã¢ã«ã³ãŒã«é£²æãèªå·±å ç«èçããŠã£ã«ãœã³ç ãGalactosemiaãFruuctosemiaãã°ãªã³ã²ã³è²¯èµç æ°ãéç©ã¿éãã®åŸŽåã ã¬ãŠãã£ãŒç ã现èãå¯çè«ããã³ãŠã€ã«ã¹ææãèè¡æµã«åœ±é¿ãäžããé害ã®ããã€ãã¯ãèèç·ç¶ç管çã«é¢é£ããå¯èœæ§ã®ããå±éºå åã®ããã€ãã§ãã ããã«ãèç·ç¶çæ²»çåžå Žã¯ãéã¢ã«ã³ãŒã«æ§å¹¹çްèç(NASH)æ²»çã§å¢å ããŒã¹ã... ãã£ãšèŠã
ããããè¬ã¯ããã®ç¹åŸŽã®é«ã掻åã«èµ·å ããããã€ãã®ç æ°ã«å¯ŸããŠäœ¿çšãããæœåšçãªæ²»çè¬ã§ã, ã¿ãŒã²ããç¹ç°æ§, äœæ¯æ§, æå°éã®éç¹ç°çãŸãã¯è¬ç©äŸåçžäºäœçš. æ¹åããããããããè¬å€ã®ããã®å£é èŠæ±ã管çãããšãè²§ããèã®éç£çããã³äœãã¿ãŒã²ããç¹å®ã®è¡çºã®ãããªäœãphysicochemicalç¹æ§ã ãããããã®Glycosylationã¯ãããããè¬å€ã®physicochemicalç¹æ§ã調ç¯ããçç©çèãæž¡ããããããã®æµžéã®ããã®ææãªäœæŠã§ãã ã°ãªã³ã·ã¬ãŒã·ã§ã³ã® ãããã 2ã€ã®ã¿ã€ãã®Nãªã³ã¯ãããç³éãŸãã¯Oãªã³ã¯ãããç³éã®ã©ã¡ãã§ããå ŽåããããŸãã ããã... ãã£ãšèŠã
Alveolar rhabdomyosarcoma(ARMS)ã¯ã骚ãçèãè»éªšãé垯ãªã©ã®èº«äœã®çµåçµç¹ããçããè»çµç¹ã®ãµã«ãã®äžçš®ã§ãã åäŸã®è «çåŠã°ã«ãŒãã2011幎ã«ãã調æ»ã«ãããšãè»çšéŒ»è «ã¯RMSã®çŽ25-40%ãå ããã ARMSã¯é幎ã§ã»ãšãã©æ€åºããããã°ãã°è ãèãèžãããã³èã«çºçããŸãã ã¢ã«ããããšãµã«ãã®æ£ç¢ºãªåå ã¯äžæã§ãããNeurofibromatosisã¿ã€ã1ãBeckwith-Wiedemannçå矀ãLi-Fraumeniçå矀ãCardio-facio-cutaneousçå矀ãCostelloçå矀ãªã©ã®ä»ã®æ¡ä»¶ã«é¢é£ä»ããããŠããŸãã ARM... ãã£ãšèŠã
ç±³åœããã³ãšãŒãããã®çäœå è¬çåŠåžå ŽããµãŒãã¹ã¿ã€ãå¥ïŒæ¯ç©åŠç ç©¶ãPKããã³PDç ç©¶ãæå€§èçšéç ç©¶ããã€ãªããŒã«ãŒæ€æ»ããã³çç©åæãåç©çŸæ£ã¢ãã«ãADMEç ç©¶ãªã©ïŒãã¢ããªã±ãŒã·ã§ã³å¥ïŒè «çåŠãççããã³å ç«åŠãå¿èåŠãç¥çµåŠãçŒç管çãç·ç¶çãä»£è¬æ§çŸæ£ãåŒåžåšçŸæ£ãææçãªã©ïŒãçµäºãŸã§ ãŠãŒã¶ãŒïŒãã€ãªãã¯ãããžãŒäŒæ¥ã補è¬äŒç€Ÿãåèšç ç©¶æ©é¢ïŒCROïŒãªã©ïŒ... ãã£ãšèŠã
ãã£ã«ã°ã¬ãã«åžå Žã€ã³ãµã€ãTicagrelorã¯ãå¿èçºäœãé床ã®èžçã«èŠãã人ã ã«ãããå¿èãè¡ç®¡ã«é¢é£ããæ·±å»ãªçåœãè ããåé¡ãé²ãããã«ãã¢ã¹ããªã³ãšäžç·ã«äœ¿çšãããŸãã ãŸããè¡æ¶²ååºã®çºçã鲿¢ããããã«äœ¿çšãããŸã å ç¶ã¹ãã³ã å¿èçºäœãé床ã®èžçã®æŽå²ãæã€æ£è ã äºæž¬æéäžã«å€§ããªæé·çã§æé·ããå¿èã®åé¡ã«èŠããé«ãå¿è匷ãããŒã«ãäžè¬çãªå»è¬åéçºãå¢å ãããåžå Žã¢ã¯ã»ã¹ã·ããªãªãæ¹åããããšãæåŸ ãããŠããŸããäžççãªticagreloråžå Žã¯è©äŸ¡ãããŸãã US$ ãã 1,145.0çŸäžå 2017幎ãCAGRãç®æããèŠèŸŒã¿ 12.3%æªæº äºæž¬æé(2018... ãã£ãšèŠã
è¡ç®¡ç¥çµçãŸãã¯éªšè»éªšçã¯ãè¡æ¶²äŸçµŠã®æ¬ åŠã«ãã骚çµç¹ã®æ»ã§ãã ãã®ãããªäœã®é·ã骚ã«å€§ãã圱é¿ããŸãããããã®èªç©ºæ©ã®Ncrosisè©ã® Avascular ã® NecrosisKneeã®Avascularã®Necrosisè¶³éŠã®è¡ç®¡ã®é°æ§ãªã¹ãã® Avascular ã® Necrosisè¡ç®¡ç¥çµçã®äžè¬çãªçç¶ã¯æ¬¡ã®ãšããã§ããæ©æé¢ç¯ç骚ãšé¢ç¯ã厩å£ãå§ããŠé¢ç¯çãå¢å çã¿ã«ããåãã®éãããç¯å²è¡ç®¡ç¥çµçã¯Xç·ãç£æ°å ±é³Žç»å(MRI)ãèšç®ãããããŒã¢ã°ã©ãã£ãŒã¹ãã£ã³(CT)ããŸãã¯æ žéªšã¹ãã£ã³ã«ãã£ãŠèšºæãããŸããäžççãªè¡ç®¡å éã®åžå Žã¯è©äŸ¡ããããšæšå®ãããŸã US$ 605.... ãã£ãšèŠã
Vitiligoã¯ç®èã®ç¶æ ã§ããç®èã®ããããèªåã®è²ã倱ããŸãã ç®èã®ç·é¢ç©ã¯ãããªãŽã®åœ±é¿ãåããããšãã§ããŸãã ãã®ç®èç ã¯äººãã人ãŸã§ããŸããŸã§ãç®ãå£ã®äžã髪ã«åœ±é¿ããŸãã ãããã®åºãããéãäºæž¬ããã®ã¯å°é£ã§ãã ãŽã£ããªãŽã®å€§ããªçç¶ã¯ãçœãæç¹ãç®èã®ãããã®åºçŸã§ãã ã»ã°ã¡ã³ã¿ã«ãããªãŽãéã»ã°ã¡ã³ã¿ã«ããã£ãªãŽãªã©ã®2ã€ã®äž»èŠãªã¿ã€ãããããŸãã Calcineurin InhibitorsãCorticosteroidsãããã³Psoralensã¯ãVictiligoç æ°ã®æ²»çã®ããã«å»åž«ã«ãã£ãŠç€ºãããŠããããã€ãã®äž»èŠãªè¬ã§ãã äºæž¬æéäžãåžå Žã®çææé·ã... ãã£ãšèŠã
ç±³åœã®ã¢ãã³ããã³å€§éº» API åžå ŽãAPI ã¿ã€ãå¥ (ã¢ãã³ããã³å€§éº»)ããšã³ããŠãŒã¶ãŒå¥ (ãã€ãªå»è¬åäŒç€Ÿããã³ç ç©¶æ©é¢)... ãã£ãšèŠã
ãžã§ããªãã¯è£œåã®éèŠã¯ãäžåç±³ã®å»è¬ååžå Žã§é«ããªã£ãŠããŸãã ãŸããå»è¬åã¡ãŒã«ãŒã®å€§åã¯ãåèšè£œé æ©é¢(CMO)ãžã®è£œé 掻åãåŸã ã«ã¢ãŠããœãŒã·ã³ã°ããŠããŸããã©ãã³ã¢ã¡ãªã«å»è¬å CMO åžå Žã¯äŸ¡å€ããããšæšå®ããã US$15,173.6çŸäž ãåãåãã 2020幎1æ19æ¥ å±ç€ºäºå® ã«ã°ã¬ ã«ã€ã㊠14.7%(çšæ) äºæž¬æéãè¶ ã㊠(2020-2027).ãããã£ãŒã« 1. ã©ãã³ã¢ã¡ãªã«ã®è¬å€ãããã¯ãCMO åžå Žã·ã§ã¢(%), åœå¥, 2020æ ¢æ§çŸæ£ã®å¢å€§ã¯ãäºæž¬æéã«ããã£ãŠåžå Žæé·ãä¿é²ããããšãæåŸ ãããŸãããšãã°ãIncidência de Câncer n... ãã£ãšèŠã